Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2006
  • Online publication date: February 2010

19 - Coagulation defects as a cause for menstrual disorders

Summary

Menorrhagia

Introduction

Normal menstruation occurs every 21–35 days lasting on average 7 days. Normal blood loss is between 25 and 69 ml per cycle. Menstrual abnormalities can be characterized by their flow and regularity. Menorrhagia is defined as bleeding of over 80 ml with menstruation. Menometrorrhagia is irregular heavy menstruations. Menstrual abnormalities can be caused by multiple etiologies. These include gynecological abnormalities of the uterus, hormonal disorders, and systemic disorders. Prior reports have identified causes for excessive bleeding in only 50% of patients. The estimated prevalence of menorrhagia in healthy women is between 9% and 14%. Menorrhagia has been found to be a reliable predictor for coagulation and platelet disorders. In the absence of a readily identifiable cause, all adolescents with menorrhagia, especially those with anemia, should be examined for an undiagnosed coagulation defect.

Quality of life evaluations were shown to be poorer in all areas in women who had inherited bleeding disorders. As compared to controls, women with menorrhagia found that they accomplished less than they would like during menses, and their heavy flow limited their activities and the kind of work they could do. Forty-six percent of type 1 von Willebrand disease (VWD) patients reported losing on average 4 days from work or school due to menorrhagia.

The gynecologist has a unique role in being the primary care giver, who generally is the first practitioner to whom the patient presents with menstrual bleeding problems.

REFERENCES
Hallberg, L., Hogdahl, A. M., Nilsson, L., et al. Menstrual blood loss – a population study. Variation at different ages and attempts to define normality. Acta Obstet. Gynecol. Scand., 1966; 45: 320–51.
Oehler, M. K., Rees, M. C.Menorrhagia: an update. Acta Obstet. Gynecol. Scand., 2003; 82: 405–22.
Eijkeren, M. A., Christianens, G. C., Sixma, J. J., et al. Menorrhagia: A review. Obstet. Gynecol. Surv., 1989; 44: 421.
Edlund, M., Bolmback, M., Schoultz, B., et al. On the value of menorrhagia as a predictor for coagulation disorders. Am. J. Hematol., 1996; 53: 234–8.
Kadir, R. A., Sabin, C. A., Pollard, D., et al. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia, 1998; 4: 836–41.
Kouides, P. A., Phatak, P. D., Burkart, P., et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia, 2000; 6: 643–8.
Markee, J. E.Menstruation in intraocular endometrial transplants in the Rhesus monkey. Contrib. Embryol., 1940; 28: 221–308.
Bartelmez, G. W.Histological studies on the menstruating mucous membrane of the human uterus. Contrib. Embryol., 1933; 24: 141–86.
Fauvel, F., Grant, M. E., Legrand, Y. J., et al. Interaction of blood platelets with a microfibrillar extract from adult bovine aorta: requirement for von Willebrand factor. Proc. Natl. Acad. Sci. USA, 1983; 80: 551–4.
Christianes, G. C., Sixma, J. J., Haspels, A. A.Morphology of haemostasis in menstrual endometrium. Br. J. Obstet. Gynaecol., 1980; 87: 425–39.
Fraser, I. S., McCarron, G., Markham, R.A preliminary study of factors influencing perception of menstrual blood loss volume. Am. J. Obstet. Gynecol., 1984; 149: 788–93.
Higham, J. M., O'Brien, P. M., Shaw, R. W.Assessment of menstrual blood loss using a pictorial chart. Br. J. Obstet. Gynaecol., 1990; 97: 734–9.
Reid, P. C., Coker, A., Coltart, R.Assessment of menstrual blood loss using a pictorial chart: a validation study. Br. J. Obstet. Gynaecol., 2000; 107: 320–2.
Wyatt, K. M., Dimmock, P. W., Walker, T. J., et al. Determination of total menstrual blood loss. Fertil. Steril., 2001; 76: 125–31.
Dilley, A., Drews, C., Lally, C., et al. A survey of gynecologists concerning menorrhagia: perceptions of bleeding disorders as a possible cause. J. Womens Health Gend. Based Med., 2002; 11: 39–44.
Kadir, R. A., Aledort, L. M.Obstetrical and gynaecological bleeding: a common presenting symptom. Clin. Lab. Haematol., 2000; 22 (Suppl. 1): 12–6; discussion, 30–2.
Ellis, M. H., Beyth, Y.Abnormal vaginal bleeding in adolescence as the presenting symptom of a bleeding diathesis. J. Pediatr. Adolesc. Gynecol., 1999; 12: 127–31.
Werner, E. J., Broxson, E. H., Tucker, E. L., et al. Prevalence of von Willebrand disease in children: a multiethnic study. J. Pediatr., 1993; 123: 893–8.
Rodeghiero, F., Castaman, G., Dini, E.Epidemiological investigation of the prevalence of von Willebrand's disease. Blood, 1987; 69: 454–9.
Ruggeri, Z. M.Mechanisms initiating platelet thrombus formation. Thromb. Haemost., 1997; 78: 611–16. Erratum in: Thromb. Haemost., 1997; 78: 1304.
Kadir, R. A., Economides, D. L., Sabin, C. A., et al. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia, 1999; 5: 40–8.
Goodman-Gruen, D., Hollenbach, K.The prevalence of von Willebrand disease in women with abnormal uterine bleeding. J. Womens Health Gend. Based Med., 2001; 10: 677–80.
Shankar, M., Lee, C. A., Sabin, C. A., et al. Von Willebrand disease in women with menorrhagia: a systematic review. Br. J. Obstet. Gynaecol., 2004; 111: 734–40.
Federici, A. B., Mannucci, P. M.Advances in the genetics and treatment of von Willebrand disease. Curr. Opin. Pediatr., 2002; 14: 23–33.
Kadir, R. A., Economides, D. L., Sabin, C. A., et al. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb. Haemost., 1999; 82: 1456–61.
Edlund, M., Blomback, M., Schoultz, B., et al. On the value of menorrhagia as a predictor for coagulation disorders. Am. J. Hematol., 1996; 53: 234–8.
Onundarson, P. T., Gudmundsdottir, B. R., Arnfinnsdottir, A. V., et al. Von Willebrand factor does not vary during normal menstrual cycle. Thromb. Haemost., 2001; 85(1): 183–4.
Werner, E. J., Abshire, T. C., Giroux, D. S., et al. Relative value of diagnostic studies for von Willebrand disease. J. Pediatr., 1992; 121: 34–8.
Coccia, M. R., Barnes, H. V.Hypothyroidism and acquired von Willebrand disease. J. Adolesc. Health, 1991; 12: 152–4.
Blesing, N. E., Hambley, H., McDonald, G. A.Acquired von Willebrand's disease and hypothyroidism: report of a case presenting with menorrhagia. Postgrad. Med. J., 1990; 66: 474–6.
Mannucci, P. M.Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 1997; 90: 2515–21.
Rodeghiero, F., Castaman, G., Mannucci, P. M.Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb. Haemost., 1996; 76(5): 692–6.
Siegel, J. E., Kouides, P. A.Menorrhagia from a haematologist's point of view. Part II: management. Haemophilia, 2002: 8: 339–47.
Federici, A. B., Mazurier, C., Berntorp, E., et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood, 2004; 103: 2032–8.
Castaman, G., Lattuada, A., Mannucci, P. M., et al. Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br. J. Haematol., 1995; 89: 147–51.
Alperin, J. B.Estrogens and surgery in women with von Willebrand's disease. Am. J. Med., 1982; 73: 367–71.
David, J. L., Gaspard, U. J., Gillain, D., et al. Hemostasis profile in women taking low-dose oral contraceptives. Am. J. Obstet. Gynecol., 1990; 163: 420–3.
Beller, F. K., Ebert, C.Effects of oral contraceptives on blood coagulation. A review. Obstet. Gynecol. Surv., 1985; 40(7): 425–36.
Foster, P. A.The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost., 1995; 74: 784–90.
Cederblad, G., Hahn, L., Korsan-Bengtsen, K., et al. Variations in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle. Haemostasis, 1977; 6: 294–302.
Ong, Y. L., Hull, D. R., Mayne, E. E.Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia, 1998; 4: 63–5.
Mohri, H.High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. J. Thromb. Thrombolysis, 2002; 14: 255–7.
Dunn, C. J., Goa, K. L.Tranexamic acid: a review of its use in surgery and other indications. Drugs, 1999; 57: 1005–32.
Vermylen, J., Verhaegen-Declercq, M. L., Verstraete, M., et al. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb. Diath. Haemorrh., 1968; 20: 583–7.
Bonnar, J., Sheppard, B. L.Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ, 1996; 313: 579–82.
Eijkeren, M. A., Christiaens, G. C., Scholten, P. C., et al. Menorrhagia. Current drug treatment concepts. Drugs, 1992; 43: 201–9.
Ong, Y. L., Hull, D. R., Mayne, E. E.Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia, 1998; 4: 63–5.
Mehta, B. C., Parekh, D. S.Epsilon-amino-caproic acid in the treatment of menorrhagia. J. Postgrad. Med., 1977; 23: 121–3.
Nitu-Whalley, I. C., Lee, C. A.Acquired von Willebrand syndrome – report of 10 cases and review of the literature. Haemophilia, 1999; 5: 318–26.
Federici, A. B., Rand, J. H., Bucciarelli, P., et al. Acquired von Willebrand syndrome: data from an international registry. Thromb. Haemost., 2000; 84: 345–9.
Garewal, G., Ahluwalia, J.Platelet function disorders. Indian J. Pediatr., 2003; 70: 983–7.
Saxena, R., Gupta, M., Gupta, P. K., et al. Inherited bleeding disorders in Indian women with menorrhagia. Haemophilia, 2003; 9: 193–6.
Philipp, C. S., Dilley, A., Miller, C. H., et al. Platelet functional defects in women with unexplained menorrhagia. J. Thromb. Haemost., 2003; 1: 477–84.
Markovitch, O., Ellis, M., Holzinger, M., et al. Severe juvenile vaginal bleeding due to Glanzmann's thrombasthenia: case report and review of the literature. Am. J. Hematol., 1998; 57: 225–7.
DiMichele, D. M., Hathaway, W. E.Use of DDAVP in inherited and acquired platelet dysfunction. Am. J. Hematol., 1990; 33: 39–45.
Bennett, J. S.Disorders of platelet function: evaluation and treatment. Cleve. Clin. J. Med., 1991; 58: 413–17.
Bevan, J. A., Maloney, K. W., Hillery, C. A., et al. Bleeding disorders: A common cause of menorrhagia in adolescents. J. Pediatr., 2001; 138: 856–61.
Smith, Y. R., Quint, E. H., Hertzberg, R. B.Menorrhagia in adolescents requiring hospitalization. J. Pediatr. Adolesc. Gynecol., 1998; 11: 13–15.
Tomer, A., Schreiber, A. D., McMillan, R., et al. Menstrual cyclic thrombocytopenia. Br. J. Haematol., 1989; 71: 519–24.
Bolton-Maggs, P. H., Patterson, D. A., Wensley, R. T., et al. Definition of the bleeding tendency in factor XI-deficient kindreds – a clinical and laboratory study. Thromb. Haemost., 1995; 73: 194–202.
Kadir, R. A., Economides, D. L., Lee, C. A.Factor XI deficiency in women. Am. J. Hematol., 1999; 60: 48–54.
Sapuri, M., Amoa, A. B., Kariwiga, G., et al. A case of factor V deficiency presenting as menorrhagia. P. N. G. Med. J., 1997; 40: 92–5.
Bennett, K., Daley, M. L., Pike, C.Factor V deficiency and menstruation: a gynecologic challenge. Obstet. Gynecol., 1997; 89: 839–40.
White, B., O'Connor, H., Smith, O. P.Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency. Blood Coagul. Fibrinolysis 2000; 11: 155–7.
Fasouliotis, S. J., Shushan, A.Severe menorrhagia due to factor VII deficiency successfully treated by thermal balloon endometrial ablation. J. Am. Assoc. Gynecol. Laparosc., 2003; 10: 116–18.
Eijkeren, M. A., Christiaens, G. C., Haspels, A. A., et al. Measured menstrual blood loss in women with a bleeding disorder or using oral anticoagulant therapy. Am. J. Obstet. Gynecol., 1990; 162: 1261–3.
Milad, M. P., Valle, R. F.Emergency endometrial ablation for life-threatening uterine bleeding as a result of a coagulopathy. J. Am. Assoc. Gynecol. Laparosc., 1998; 5: 301–3.
Lee, C. A.Women and inherited bleeding disorders: menstrual issues. Semin. Hematol., 1999; 36: 21–7.
Nitu-Whalley, I. C., Griffioen, A., Harrington, C., et al. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am. J. Hematol., 2001; 66: 280–4.
Kouides, P. A.Obstetric and gynaecological aspects of von Willebrand disease. Best Pract. Res. Clin. Haematol., 2001; 14: 381–99.
Foster, P. A.A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost., 1995; 74: 1370–8.
Federici, A. B., Mannucci, P. M.Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia., 1998; 4 (Suppl. 3): 7–10.
Mannucci, P. M.Treatment of von Willebrand's Disease. N. Engl. J. Med., 2004; 351: 683–94.
Mannucci, P. M., Chediak, J., Hanna, W., et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood, 2002; 99: 450–6.
Biggs, R., Matthews, J. M.The treatment of haemorrhage in von Willebrand's disease and the blood level of factor VIII (AHG). Br. J. Haematol., 1963; 9: 203–14.
Federici, A. B., Baudo, F., Caracciolo, C., et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia, 2002; 8: 761–7.